Mechanistic Studies of Psilocybin in Headache Disorders

Randomized, parallel-group study comparing a single oral 10 mg dose of psilocybin with a 2.5 mg THC control in migraine patients and healthy controls to probe mechanisms underlying reduced headache burden observed in prior work.

Outcomes include resting-state fMRI, SV2A PET for synaptic density, peripheral inflammatory markers, actigraphy for circadian rhythms, and sleep EEG measured before and one week after dosing.